Showing 7491-7500 of 8649 results for "".
- Implandata’s Receives CE Mark for the EYEMATE-SC Biosensor for Remote Glaucoma Carehttps://modernod.com/news/implandatas-receives-ce-mark-for-the-eyemate-sc-biosensor-for-remote-glaucoma-care/2479310/Implandata Ophthalmic Products announced that its EYEMATE-SC biosensor has obtained CE Mark. This device is used in conjunction with the EYEMATE system for digitally enabled remote glaucoma monitoring and management. The patented EYEMATE system is the world’s only clinically-validated pro
- Santen to Host Dry Eye Disease Panel at Inaugural European Dry Eye Society Congress (EuDEC)https://modernod.com/news/santen-to-host-dry-eye-disease-panel-at-inaugural-european-dry-eye-society-congress-eudec/2479305/Santen EMEA announced it is taking place in the inaugural European Dry Eye Society Congress (EuDEC), which will be held virtually on June 18-19, 2021. Santen will host an international panel of experts for an online s
- Lenz Therapeutics Debuts with $47 Million Series A Financinghttps://modernod.com/news/lenz-therapeutics-debuts-with-47-million-series-a-financing/2479301/Lenz Therapeutics debuted today with a $47 million Series A financing to move the company’s lead asset, an eyedrop formulation of aceclidine, toward an NDA submission for the treatment of presbyopia. The financing was
- The Vision Council Releases Results of the 2020 Internet Influence Reporthttps://modernod.com/news/the-vision-council-releasese280afresults-of-the-2020-internet-influence-report/2479298/The Vision Council has released the results of the “Internet Influence Report.” Conducted in December 2020, the special interest consumer report examines the role of the Internet among consumers who recently purchased different types of eyewear. The Vision Council fielded
- CORE Summarizes BCLA CLEAR Guidance for Contact Lens Practitionershttps://modernod.com/news/core-summarizes-bcla-clear-guidance-for-contact-lens-practitioners/2479297/The latest issue of
- Biogen Fails to Meet Primary or Secondary Endpoints in Phase 3 Gene Therapy Study in Choroideremiahttps://modernod.com/news/biogen-fails-to-meet-primary-or-secondary-endpoints-in-phase-3-gene-therapy-study-in-choroideremia/2479291/Biogen announced topline results from the phase 3 STAR study of timrepigene emparvovec (BIIB111/AAV2-REP1), an investigational gene therapy for the potential treatment of choroideremia. The STAR study did not meet its primary endpoint of proportion of participants with a ≥15 letter improvement fr
- Reed Exhibitions Unveils New Brand Identityhttps://modernod.com/news/reed-exhibitions-unveils-new-brand-identity/2479287/Reed Exhibitions announced its evolution to RX, with a refreshed visual identity and updated brand positioning, according to The Vision Council. Building on its flagship events business, the company is leveraging its capabilities in data and technology to create
- US to Buy 500 Million Doses of Pfizer, BioNTech COVID-19 Vaccine for Donation to Poorest Nationshttps://modernod.com/news/us-to-buy-500-million-doses-of-pfizer-biontech-covid-19-vaccine-for-donation-to-poorest-nations/2479284/Pfizer and BioNTech said Thursday that they will provide 500 million doses of the COVID-19 vaccine BNT162b2 to the US government at a not-for-profit price to support immunization programs in low- and lower-middle-income countries, according to FirstWord. The companies noted that 200 million doses
- Glaukos Completes Patient Enrollment in US NDA Phase 3 Clinical Trials for iDose TRhttps://modernod.com/news/glaukos-completes-patient-enrollment-in-us-nda-phase-3-clinical-trials-for-idose-tr/2479280/Glaukos announced the completion of patient enrollment and randomization in its FDA new drug application (NDA) phase 3 clinical trials for the iDose TR sustained-release travoprost implant. The iDose TR phase 3 clinical program consists of two prospective, randomized, double-
- EyeYon Medical Receives CE Mark for its EndoArt Implant to Treat Chronic Corneal Edemahttps://modernod.com/news/eyeyon-medical-receives-ce-mark-for-its-endoart-implant-to-treat-chronic-corneal-edema/2479277/EyeYon Medical announced that it has received CE Mark for its EndoArt after clinical trials demonstrated safety and efficacy for treating chronic corneal edema. EyeYon says the EndoArt is the world’s first and only synthetic implant that replaces the human endothelium that the human